[CAS NO. 107753-78-6] Zafirlukast

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [107753-78-6]

Catalog

HY-17492

Brand

MCE

CAS

107753-78-6

DESCRIPTION [107753-78-6]

Overview

MDL	MFCD00864775
Molecular Weight	575.68
Molecular Formula	C31H33N3O6S
SMILES	O=C(OC1CCCC1)NC2=CC3=C(N(C)C=C3CC4=CC=C(C(NS(=O)(C5=CC=CC=C5C)=O)=O)C=C4OC)C=C2

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]J Mol Histol. 2021 May 11.

Summary

Zafirlukast (ICI 204219) is a potent orally active leukotriene D ₄ ( LTD ₄ ) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

IC50 & Target

LTD ₄

In Vivo

Zafirlukast is a peptidyl leukotriene antagonist and inhibitor of LTD ₄ . After 13 weeks of exposure, the yield of lung tumors is significantly decreased by both dose levels of Zafirlukast (270 and 540 mg/kg), the high dose of Zileuton (1200 mg/kg), and the combinations containing 600 mg/kg Zileuton with either Zafirlukast or MK-866. The efficacy of the combination containing Zileuton and Zafirlukast to prevent lung tumors is not significantly different from the efficacy of either inhibitor administered alone. Although when administered alone at the dose level in their combination, neither Zileuton or MK-886 prevents lung tumors; the combination containing them does significantly prevent tumors. In contrast, the combination containing Zafirlukast and MK-886 does not reduce the yield of tumors, whereas Zafirlukast administered alone does significantly reduce the yield of tumors ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04339140	Dana-Farber Cancer Institute\|National Institutes of Health (NIH)\|National Cancer Institute (NCI)	Ovarian Cancer	June 24, 2020	Phase 2
NCT01283061	Dr. Reddy´s Laboratories Limited	Healthy	December 2007	Phase 1
NCT02950480	University of California, San Francisco	Breast Cancer	March 13, 2017	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 173.71 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7371 mL	8.6854 mL	17.3708 mL
5 mM	0.3474 mL	1.7371 mL	3.4742 mL
10 mM	0.1737 mL	0.8685 mL	1.7371 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (3.61 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.61 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Carbamic acid, N-[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester

Carbamic acid, [3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester

ICI 204219

Cyclopentyl 3-[2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl]-1-methylindole-5-carbamate

Zafirlukast

Accolate

Vanticon

S 1633

[3-[2-Methoxy-4-(toluene-2-sulfonylaminocarbonyl)-benzyl]-1-methyl-1H-indol-5-yl]-carbamic acid cyclopentyl ester